A Bridging Study to Evaluate Safety of ComBe Five (Liquid) (Combined Pentavalent DTwP-rHepB-Hib Vaccine) Made in India, in Healthy Vietnamese Children Aged From 8 - 10 Weeks as a 3-dose Series, Interval for Each Dose is 4 Weeks
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 330
- 试验地点
- 2
- 主要终点
- Frequency and rate of the adverse effects and severity of immediate adverse events (Local and General) within 30 minutes after vaccination.
研究概览
简要总结
An open label, non-comparative bridging study to evaluate the safety of pentavalent vaccine ComBe Five (Liquid) made in India, in healthy Vietnamese children aged from 8 - 10 weeks as a 3-dose series, interval for each dose is 4 weeks
详细描述
The trial is a bridging Study to evaluate safety of pentavalent vaccine ComBe Five (Liquid) made in India, in healthy Vietnamese children aged from 8 - 10 weeks as a 3-dose series, interval for each dose is 4 weeks. 330 subjects will be enrolled in Binh Luc and Ly Nhan district, Ha Nam province. These subjects will be received 3 doses (0.5ml/dose) ComBe Five (Liquid), the first dose will be administered at 8-10 weeks of age.
The frequency, rate and severity of immediate adverse events within 30 minutes after vaccination, solicited and unsolicited AE within 28 days after vaccination, the frequency and rate of SAE within 28 days after the first vaccination will be recorded as evidences for ComBeFive (Liquid) safety assessment. The subjects to be included from this trial would be representative of the population of Vietnam.
The protocol has been reviewed and approved by Vietnam Military Medical University IRB and Vietnam Ministry of Health IEC and Vietnam Minister of Health.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 8 Weeks 至 10 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject must meet all criteria below to participate in study:
- •Healthy children, both genders, age from 8 -12 weeks at screening visit and the first dose (visit 1)
- •Weight ≥ 3.300 gram at Screening visit and receive the first dose
- •Understand and follow the study
- •Mother of children have serum negative for HIV, HBV and HCV on blood test results or antenatal tests report book.
- •Children or mother don't participate in other clinical study scheduled during the study.
- •Parent/ legal guardian can understand and have ability to follow protocol.
- •Parent/ legal guardian voluntary write consent to participate in the study.
- •Parent/ legal guardian of subject have ability to comply with the process of study.
- •Parent/ legal guardian of subject who intends to remain in the area with the participant during the study period.
排除标准
- •Subject have one of criteria below must not participate in study:
- •Fever (temperature ≥37.5oC) or loses temperature (≤35.5 oC) or disease/ infection chronic
- •Subjects who had received DPT
- •Subjects who had received immunosuppressant therapy
- •Subjects with a known or doubt hypersensitivity of allergic reaction to any component of the study vaccine
- •Subjects who had any signs or symptoms of functional disorder, especially central nervous system.
- •Subjects who had haemophilia or received treatment anticoagulant drug, had a risk of serious bleeding when intramuscular injection.
- •Subjects who had a family history of SIDS (Sudden Infant death syndrome)
- •Subjects intend to surgery scheduled during the study
- •Subjects who had received any blood products, corticosteroid cytotoxic drugs, radiotherapy.
- •Subjects and mother who had participated in other clinical trial within 30 days priors to vaccination with study drug, or those who had another clinical trial scheduled during the study.
- •Can't afford or not ready follow protocol
- •Any criteria that, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence
研究组 & 干预措施
Pentavalent vaccine
3 Dose, interval for each dose is 4 weeks. The first dose will be received at 8-10 weeks of age
干预措施: ComBe Five (Liquid) (Biological)
结局指标
主要结局
Frequency and rate of the adverse effects and severity of immediate adverse events (Local and General) within 30 minutes after vaccination.
时间窗: 30 minutes after vaccination
Frequency and rate of adverse effects and severity of solicited adverse events (Local and General) within 7 days after each vaccination
时间窗: For 7 days after each vaccination
Frequency and rate of adverse effects and severity of unsolicited adverse events (Local and General) during 28 days after each vaccination
时间窗: For 28 days after each vaccination
Frequency and rate of adverse effects and severity of Serious Adverse Events (Local and General) during 28 days after each vaccination
时间窗: For 28 days after each vaccination
次要结局
未报告次要终点
研究者
Pham Ngoc Hung
Principal Investigator
Vietnam Military Medical University